Study record

Evaluation of Serum Humanin and MOTS-c Peptide Levels in Patients with COVID-19 and Healthy Subjects

Saracaloglu A, Mete AÖ, Ucar DF et al. · Curr Protein Pept Sci · 2023

Human obs.Endogenous MOTS-c measuredEvidence tier B
PubMed 36799414doi:10.2174/1389203724666230217101202Compare with another study

What this study reported

Measured circulating MOTS-c and humanin by ELISA in adults with COVID-19 before and during antiviral drug therapy and in healthy volunteers. Found higher serum MOTS-c and lower serum humanin in the COVID-19 group than in the control group, and reported no significant change in either peptide between the pre-treatment and post-treatment samples.

Limitations

Small single-centre sample of 30 patients; no reported adjustment for disease severity, comorbidity or concomitant medication, and the paired samples span only the first week of therapy with no untreated patient comparison.

Study record

Annotated fields for this study
Study modelHuman observational
Substance studiedEndogenous MOTS-c measuredNaturally occurring MOTS-c was measured; nothing was given.
Specieshuman
System studiedAdults hospitalised with COVID-19 sampled before and during antiviral drug therapy, and gender-matched healthy volunteers
Populationadults with COVID-19 and gender-matched healthy volunteers
DesignCase-control study with repeated sampling during antiviral therapy
Sample size as reported30 adults with COVID-19 and 32 gender-matched healthy volunteers
Control group32 gender-matched healthy volunteers
Route (data field only)Not reported
Endpoints measuredserum MOTS-c; serum humanin; change in peptide levels with antiviral therapy
Pathways measuredNot reported
Research areasInflammation & immunity
Evidence tierB — Other human study
Publication typesJournal Article

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
Human
Sample size
Small
Controls
Limited
Outcome validity
Exploratory
Support for its own conclusion
Weak

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.